The long-term observation of patients with rheumatoid arthritis who achieved a biological disease-modifying antirheumatic drug-free condition with adalimumab

Satoshi Itoa Department of Rheumatology, Niigata Rheumatic Center, Shibata, JapanCorrespondence[email protected]

Shunsuke Sakaia Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan;b Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

Yoichi Kurosawaa Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan;b Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

Daisuke Kobayashia Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan;b Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

Ryo Okabayashia Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan

Asami Abea Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan

Hiroshi Otania Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan

Kiyoshi Nakazonoa Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan

Akira Murasawaa Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan

Ichiei Naritab Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

Hajime Ishikawaa Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan

show all

Click to increase image sizeClick to decrease image size

Conflict of interest

S. Ito received a speaking fee (approximately US$ 5000) from Eisai Co., Ltd.; Mitsubishi Tanabe Pharma Co., Ltd., and Janssen pharmaceutical K.K. The other authors declare no conflicts of interest in association with this study.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

The long-term observation of patients with rheumatoid arthritis who achieved a biological disease-modifying antirheumatic drug-free condition with adalimumab

Information for

Open access

Opportunities

Help and information

The long-term observation of patients with rheumatoid arthritis who achieved a biological disease-modifying antirheumatic drug-free condition with adalimumab

Conflict of interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature